All studies
Endocrinology · EHR · England
Ryan 2026
Type 2 diabetes
DAG reportedQBA performedITTSuperiorityAcademia4/5 disclosures
Comparisons
2
In the analysis
0
2 withheld
Target trials
1
Emulations reported
2
2 treatments
Design and methods
- Estimand
- ITT
- Design hypothesis
- Superiority
- Matching / weighting
- Propensity-score weighting
- Analysis method
- Weighted Cox proportional hazards model
- Missing data
- Multiple imputation
- DAG
- Yes
- QBA
- Yes
Data and sample
- Data type
- EHR
- Data sources
- CPRD Aurum linked data
- Geography
- England
- Eligible sample
- 62503
- Treated
- 13239
- Control
- 49264
- Emulations
- 2
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Available from CPRD subject to approval
- Code availability
- https://github.com/dkdryan/empa_reg_tte
- Conflicts of interest
- Declared: Industry
- COI institutions
- Relationships listed on ICMJE disclosures
- Funding
- Declared: Public
- Funders
- National Institute for Health and Care Research
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2026_Ryan_EMPAREG
- DOI
- 10.1136/bmjdrc-2025-005672
- Affiliations
- University of Oxford and UK academic collaborators
- Sector
- Academia
- Target trials (study level)
- EMPA-REG OUTCOME
- Registration
- NCT01131676